What this study is
The purpose of this study is to examine a psychotherapeutic and psycho-educational intervention offered in virtual settings to caregivers of youth with cancer. Human subjects must be used because they are the object of the intervention.
What's being tested
- GOLD Program
Intervention · BEHAVIORAL
Participant will receive a 2-hour interventional session
- Treatment as usual (TAU)
Intervention · BEHAVIORAL
Participant will receive treatment-As-Usual which consist of information about diagnosis routinely-disseminated by personnel and providers.
Study details
- Official title
- Brief Intervention to Reduce Anxiety and Promote Resilience in Caregivers of Youth With Cancer
- Sponsor
- Stanford University
- Conditions
- Cancer
- Enrolling
- 40 people
- Starts
- 2022-09-21
- Est. completion
- 2027-06-30
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 8 Years – 18 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Child (0-17yrs) with recent (<12 mo) cancer diagnosis
- Fluent in English
- Consent to research
- Recent (<12 mo) cancer diagnosis in child
- 8-17 Years old
- Provides assent to participate in the study
You can't join if
- Parents
- Lack of proficiency in written and spoken English
- Parent is under age 18
- Active Suicidal Ideation
- Child with cancer does not provide assent
- Children
- Cannot read English
- Parent is not enrolled in the study Anyone who is not a caregiver of children who have been diagnosed with cancer within the past 12 months will be excluded.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openStanford Cancer Institute
San Francisco, California, United States
- Victoria E. Cosgrove, PhD · Contact650-995-6848veileen@stanford.edu
- Sheri Spunt, MD · Sub-investigator
Recruiting
Study team
Sponsor
Stanford University
Study ID IRB-54525
Principal investigator
Victoria E. Cosgrove, PhD
Stanford University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.